An FDA panel is discussing waiving restrictions on certain peptides to meet rising demand for unapproved therapies.
Dr. Priya Nair
Pharmacologist · July 23, 2026
Regulatory bodies are re-evaluating compounding category lists as clinical evidence for peptide safety profiles expands worldwide.
Recommended by Biohack Health
Independent third-party tested, with certificates of analysis published for every batch. Educational use only — not for human consumption.
The regulatory landscape shifted through three separate mechanisms: a compounding decision in 2023, shortage resolutions in 2024-25, and an enforcement campaign in 2026.
ResearchMost writing about TB-500 cites research about Thymosin Beta-4. Those are not the same thing, and the gap between them is the most important fact about this compound.
ResearchBetween December 2025 and July 2026, four Phase 3 trials reported topline results. The compound moved from a promising signal to a late-stage asset with data across obesity, diabetes, and CVD.